Adolescents born in 2007 or before can register on Co-WIN to book vaccine slots or can simply walk into vaccination centres, the Union health ministry said in a document.
COVID-19 vaccine stock which has not been utilised in private hospitals and nearing expiry has been taken up for redistribution by respective state governments, as advised by the Union government.
The health ministry has reportedly placed a purchase order for one crore dozes of Zydus Cadila's three-dose Covid-19 vaccine.
The vaccine will be administered using a needle-free applicator called "PharmaJet", as opposed to the traditional syringes.
The Union Health Ministry is learnt to have given the go ahead to initiate the preparatory work for the introduction of the indigenously developed world's first DNA-based Covid jab.
To administer the needle-free ZyCov-D vaccine, a disposable painless jet applicator costing Rs 93 is required for each dose, which would take the price to Rs 358 per dose.
Director of Family Welfare and nodal officer of COVID vaccination Dr Bijay Panigrahi said the orientation-cum-training programme is being conducted in phases.
Hospitals say stocks of Covishield, Covaxin have piled up, cite lack of needle-free vaccine applicators
The Ahmedabad-based company had projected the vaccine as a painless vaccine that has to be administered in three doses.
Sources added that a few more rounds of negotiations are likely this week before a government procurement price, as well as price of the vaccine in private hospitals can be fixed.
As far as the price at which it will be procured is concerned, Union Health Secretary Rajesh Bhushan told a press conference that the government is in talks with the manufacturer.
The permission granted by DCGI in August was for a three-dose schedule, which was tested for efficacy in the Phase 3 clinical trials.
Further, a decision on whether all children or only those with co-morbidities will be administered the COVID-19 vaccine on priority has not yet been taken, the government said on Thursday.
Vaccination for adolescents and kids with serious comorbidities, however, are likely to start in October when sufficient doses of ZyCoV D is available.
Sharvil Patel said Zydus Cadila is actively looking at ramping up manufacturing both domestically through partnerships and also outside of the country.